Metrics as of 10/15/2026, 11:03 AM (Berlin time), refresh in progress.
Bioventus Stock
Bioventus Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Robert Claypoole
- Employees
- 950
- Market cap
- $922 M
- IPO
- 11/02/2021
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products,…
Bioventus stock: price history
1D
-0.4%
1W
+5.7%
1M
+2.6%
6M
+27.8%
YTD
+81.5%
1Y
+102.1%
2Y
+7.4%
5Y
-1.0%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~127% stronger price swings than usual
Ask the agents about Bioventus
Analyst assessment of Bioventus
PRICE TARGET LOW
US$18.00
CONSENSUS
US$18.33
MEDIAN
US$18.00
PRICE TARGET HIGH
US$19.00
0
STRONG BUY
5
BUY
2
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 17/08/2026
Bioventus stock metrics
P/E
16.8
P/B
4.01
EV/EBITDA
11.14
RETURN ON EQUITY
14.6%
NET MARGIN
21.8%
DEBT/EQUITY
1.16
DIVIDEND YIELD
0.0%
AS OF
27/06/2026
Free float & liquidity
FREE FLOAT
69.2%
FLOAT SHARES
47,249,711
AVG. DAILY VOLUME (30D)
449,284
Insider transactions (SEC)
SUTTER MARTIN P
HAWKINS WILLIAM A
NOHRA GUY P
STALNECKER SUSAN M
NEELS GUIDO J
Institutional holders
Comparable stocks
Frequently asked questions about Bioventus stock
What does Bioventus do?
Bioventus Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Robert Claypoole, the company employs around 950 people.
The IPO was on 11/02/2021; the stock trades on NASDAQ under the ticker BVS.
What do analysts say about Bioventus stock?
7 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$18.33, ranging from US$18.00 to US$19.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does Bioventus report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 127% stronger than usual.
Does Bioventus pay a dividend?
No, Bioventus currently does not pay a dividend.
Which stocks are comparable to Bioventus?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Bioventus stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bioventus against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.